[go: up one dir, main page]

FI70410B - Foerfarande foer framstaellning av farmaceutiskt aktiva inre salter av sulfooxipyrimidiniumhydroxid - Google Patents

Foerfarande foer framstaellning av farmaceutiskt aktiva inre salter av sulfooxipyrimidiniumhydroxid Download PDF

Info

Publication number
FI70410B
FI70410B FI810681A FI810681A FI70410B FI 70410 B FI70410 B FI 70410B FI 810681 A FI810681 A FI 810681A FI 810681 A FI810681 A FI 810681A FI 70410 B FI70410 B FI 70410B
Authority
FI
Finland
Prior art keywords
compounds
hydroxide
sulfooxy
inner salt
methyl
Prior art date
Application number
FI810681A
Other languages
English (en)
Finnish (fi)
Other versions
FI70410C (fi
FI810681L (fi
Inventor
John Michael Mccall
Original Assignee
Upjohn Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Upjohn Co filed Critical Upjohn Co
Publication of FI810681L publication Critical patent/FI810681L/fi
Application granted granted Critical
Publication of FI70410B publication Critical patent/FI70410B/fi
Publication of FI70410C publication Critical patent/FI70410C/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C07D251/18—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom with nitrogen atoms directly attached to the two other ring carbon atoms, e.g. guanamines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/54—Three nitrogen atoms
    • C07D251/70—Other substituted melamines

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Claims (4)

1. Menetelmä farmaseuttisesti aktiivisen sulfo-oksipyri-midiniumhydroksidin sisäisen suolan valmistamiseksi, jolla on kaava oso2o® RK N® NH„ T Y V R2 R3 jossa on 1-4 hiiliatomia sisältävä alkyyli, amino tai 1-4 hiiliatomia sisältävä monoalkyyliamino; R2 ja R^ ovat samanlaisia tai erilaisia ja ovat vety, 1-4 hiiliatomia sisältävä alkyyli, sillä edellytyksellä, että jos toinen ryhmistä R2 ja R^ on vety toinen ei ole vety tai metyyli, 3-6 hiiliatomia sisältävä alkenyyli (lukuunottamatta tyydyttymättömyyttä siinä hiilessä, joka on sitoutunut suoraan typpeen), fenyylialkyyli, jonka alkyy1iosassa on 1-3 hiiliatomia, 5-8 hiiliatomia sisältävä sykloalkyyli, tai R2 ja R^ muodostavat yhdessä typen kanssa 1-pyrrolidi-nyyli-, 1-piperidinyyli-, 4-alkyylipiperatsinyyli-, jonka alkyyliosassa on 1-3 hiiliatomia, 4-morf oi inyy 1. i - , 4-tio-morfolinyyli-, 3,6-dihydro-1-(2H)-pyridinyyli- tai 3-pyrrolin-1-yyliryhmän tai sen tautomeeristen tai solvatoi-tujen muotojen valmistamiseksi, tunnettu siitä, että yhdiste, jolla on kaava O R1\^N M i N Y N / \ R2 R3 15 7041 0 jossa , ja R3 tarkoittavat samaa kuin edellä, saatetaan reagoimaan pyridiini-rikkitrioksidi-kompleksin, tri-etvyliamiini-rikkitrioksidi-kompleksin, kloorisulfonihapon tai kloorisulfuryylikloridin kanssa inertissä liuottimessa.
2. Patenttivaatimuksen 1 mukainen menetelmä, tunnet-t u siitä, että valmistetaan 2,6-diamino-4-(1-piperidinyy-li)-1-(sulfo-oksi)-pyrimidiniumhydroksidin sisäistä suolaa.
1. Förfarande för framställning av ett farmaceutiskt ak-tivt inre sait av en sulfooxipyrlmidiniumhydroxid med formeln II oso2cP R. Θ NH
1. N - 2 if II ΎN R2 ^ ^ R3 i vilken är alkyl med 1-4 kolatomer, amino eller monoalkylamino med 1-4 kolatomer; R2 och är samma eller olika och betecknar väte, alkyl med 1-4 kolatomer, med förutsättning att om den ena av grupperna R2 och R^ betecknar väte sä är den andra ej väte eller metyl, alkenyl med 3-6 kolatomer (utesluter omättnad vid kolatomen direkt bunden tili kvävet), fenylalkyl där alkyldelen uppvisar 1-3 kolatomer, cykloalkyl med 5-8 kolatomer, eller R2 och tillsammans med kvävet bildar en 1 -pyrrolidinyl-, 1-piperidinyl-, 4-alkyl-piperazinyl-, där alkyldelen uppvisar 1-3 kolatomer, 4-morfolinyl-, 4-tio-morfolinyl-, 3,6-dihydro-1 (2H)-pyridinyl- eller 3-pyrrolin-1-ylgrupp eller tautomera eller solvatiserade former där-av, kännetecknat av att en förening med formeln
FI810681A 1980-03-10 1981-03-04 Foerfarande foer framstaellning av farmaceutiskt aktiva inre salter av sulfooxipyrimidiniumhydroxid FI70410C (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/128,995 US4287338A (en) 1980-03-10 1980-03-10 Sulfooxy-pyrimidinium, -pyridinium, and -triazinium hydroxide inner salts
US12899580 1980-03-10

Publications (3)

Publication Number Publication Date
FI810681L FI810681L (fi) 1981-09-11
FI70410B true FI70410B (fi) 1986-03-27
FI70410C FI70410C (fi) 1986-09-19

Family

ID=22437996

Family Applications (1)

Application Number Title Priority Date Filing Date
FI810681A FI70410C (fi) 1980-03-10 1981-03-04 Foerfarande foer framstaellning av farmaceutiskt aktiva inre salter av sulfooxipyrimidiniumhydroxid

Country Status (15)

Country Link
US (1) US4287338A (sv)
JP (1) JPS56150066A (sv)
AU (1) AU536166B2 (sv)
BE (1) BE887850A (sv)
CA (1) CA1154761A (sv)
CH (1) CH645626A5 (sv)
DE (1) DE3107583A1 (sv)
FI (1) FI70410C (sv)
FR (1) FR2477541A1 (sv)
GB (1) GB2071092B (sv)
HK (1) HK98088A (sv)
IT (1) IT1142667B (sv)
NL (1) NL8101114A (sv)
SE (1) SE448876B (sv)
ZA (1) ZA811057B (sv)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5514672A (en) * 1981-02-17 1996-05-07 Bazzano; Gail S. Use of retinoids and compositions containing same for hair growth
US5183817A (en) * 1981-02-17 1993-02-02 Bazzano Gail S Combinations of retinoids and minoxidil-type compounds for hair growth
US4532240A (en) * 1982-09-09 1985-07-30 Warner-Lambert Company Diaminopyrimidines
WO1986004231A1 (en) * 1985-01-25 1986-07-31 The Upjohn Company Pyrimidine sulfates for hair growth
FR2590897B1 (fr) * 1985-12-06 1988-02-19 Kemyos Bio Medical Research Sr Nouveaux derives de 6 amino 1,2-dihydro-1-hydroxy-2-imino-pyrimidine, leur procede de preparation et compositions cosmetiques les renfermant
US4927626A (en) * 1988-10-28 1990-05-22 Devillez Richard L Method for enhancement of unguis growth
FR2651122B1 (fr) * 1989-08-29 1994-10-28 Oreal Compositions destinees a etre utilisees pour freiner la chute des cheveux et pour induire et stimuler leur croissance, contenant des derives de l'amino-2 pyrimidine oxyde-3 et nouveaux composes derives de l'amino-2 pyrimidine oxyde-3.
GB8929022D0 (en) * 1989-12-22 1990-02-28 Ici Plc Diazine derivatives
GB9008818D0 (en) * 1990-04-19 1990-06-13 Ici Plc Amine derivatives
DE69108402T2 (de) * 1990-11-14 1995-10-05 Upjohn Co 5-fluor-2,4,6-pyrimidinthiaminderivate zur verhinderung des haarsausfalls.
FR2671082B1 (fr) * 1990-12-28 1993-04-16 Oreal Agent a plusieurs composants ou kit de preparation de la forme sulfo-conjuguee de composes pyrimidino- ou triazino-n-oxyde et procede de mise en óoeuvre.
FR2677884B1 (fr) * 1991-06-20 1993-07-09 Oreal Composition pour freiner la chute des cheveux a base de pyrimidines n-oxyde trisubstitues ou leurs derives sulfoconjugues, nouveaux composes pyrimidines n-oxyde ou leurs derives sulfoconjugues.
AU8681498A (en) 1997-08-01 1999-02-22 Reilly Industries, Inc. Supernucleophilic 4-substituted-pyridine catalysts, and processes useful for preparing same
EP1850663A4 (en) * 2005-02-22 2008-03-19 Cedars Sinai Medical Center USE OF MINOXIDILSULFATE AS AN ACTIVE AGAINST CANCER
TW200904437A (en) * 2007-02-14 2009-02-01 Janssen Pharmaceutica Nv 2-aminopyrimidine modulators of the histamine H4 receptor
EP2144877A1 (en) * 2007-04-04 2010-01-20 UCB Pharma, S.A. Novel pyridine derivatives, processes for preparing them, pharmaceutical compositions thereof
US8470833B2 (en) 2009-12-15 2013-06-25 Mcneil-Ppc, Inc. Hair growth and/or regrowth compositions

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3270014A (en) * 1965-07-01 1966-08-30 Upjohn Co 1, 2-dihydro-1-hydroxy-1, 3, 5-triazines
US3382248A (en) * 1965-11-01 1968-05-07 Upjohn Co 6-amino-4, 5-di(substituted amino)-1, 2-dihydro-1-hydroxy-2-iminopyrimidines
US3464987A (en) * 1966-02-21 1969-09-02 Upjohn Co 1,2-dihydro-1-hydroxy-2-imino-6-(lower alkyl)pyrimidines
US3973016A (en) * 1974-08-05 1976-08-03 Warner-Lambert Company Blood pressure reducing hydroxypyrimidines
US4021562A (en) * 1975-12-08 1977-05-03 Mead Johnson & Company 4-Tertiary-amino-2,6-diaminopyridine 1-oxides

Also Published As

Publication number Publication date
GB2071092B (en) 1983-09-07
NL8101114A (nl) 1981-10-01
GB2071092A (en) 1981-09-16
FI70410C (fi) 1986-09-19
FR2477541A1 (fr) 1981-09-11
AU536166B2 (en) 1984-04-19
IT1142667B (it) 1986-10-15
DE3107583C2 (sv) 1989-11-02
BE887850A (fr) 1981-09-09
JPS56150066A (en) 1981-11-20
SE8101421L (sv) 1981-09-11
CA1154761A (en) 1983-10-04
DE3107583A1 (de) 1982-01-07
FI810681L (fi) 1981-09-11
HK98088A (en) 1988-12-09
US4287338A (en) 1981-09-01
CH645626A5 (de) 1984-10-15
AU6737181A (en) 1981-09-17
IT8147976A0 (it) 1981-03-09
FR2477541B1 (sv) 1984-06-01
SE448876B (sv) 1987-03-23
JPH0145467B2 (sv) 1989-10-03
ZA811057B (en) 1982-03-31

Similar Documents

Publication Publication Date Title
FI70410B (fi) Foerfarande foer framstaellning av farmaceutiskt aktiva inre salter av sulfooxipyrimidiniumhydroxid
CN110352188B (zh) 氟代烯丙胺衍生物及其用途
KR101140785B1 (ko) 4-〔〔4-〔〔4-（2-시아노에테닐）-2,6-디메틸페닐〕아미노〕-2-피리미디닐〕아미노〕벤조니트릴의 제조방법
US20040009993A1 (en) Pyridopyrimidinones derivatives as telomerase inhibitors
EP0150469B1 (en) Thieno(2,3-d)pyrimidine derivatives and salts thereof
HU212133B (en) Therapeutic agents
US3169965A (en) New x-mercapto-pyrazolo
EA008446B1 (ru) Соединения имидазопиридина, способ их получения и фармацевтические композиции, которые их содержат
US3579524A (en) 2-aminoalkyl derivatives of phthalimidines
EP0229370B1 (en) Guanidinobenzoic ester derivative, a process for preparing same and pharmaceutical compositions containing same
AU677851B2 (en) Novel carbocyclic nucleoside agents useful as selective inhibitors of proinflammatory cytokines
US5574037A (en) Amino 1,3,5-triazine derivatives as agents for cardiovascular system
EP0227451A2 (en) 5,6-Dialkoxy-4-imino-2 (1H)quinazolinone derivatives
US4492696A (en) Piperazine and homopiperazine compounds
EP0551527B1 (en) Pyrroloazepine derivative
CA2049490A1 (en) Pyrrolobenzimidazoles, imidazobenzoxazinones and imidazoquinolones, process for their preparation and their use and preparations containing the compounds
CA2220140C (en) (2-morpholinylmethyl)benzamide derivatives
US5707979A (en) Phosphinic acid derivatives, their preparation and their use
EP0244352B1 (en) Pyrido[4,3-d]pyrimidine derivatives
US3378564A (en) Certain pyridyl tetrazole derivatives
NZ264062A (en) 2-[diaza-(and oxaza)cyclo(alkyl)]piperazine derivatives; pharmaceutical compositions; process for preparation
US4355031A (en) 2,3-Dihydro-3-[4-(substituted)-1-piperazinyl]-1H-isoindol-1-ones
JPS63154663A (ja) ３，５−ジ−タ−シヤリ−ブチル−４−ヒドロキシケイ皮酸アミド誘導体
GB2162843A (en) Piperazine derivatives
EP0458459A2 (en) Substituted benzhydryl 2-hydroxypropyl piperazine derivatives

Legal Events

Date Code Title Description
MM Patent lapsed
MM Patent lapsed

Owner name: THE UPJOHN COMPANY